A study comparing photon-based and proton-beam radiation therapies found that photon-based therapy resulted in better long-term survival rates, particularly among younger patients and those with ependymomas. The research suggests a potential shift in treatment guidelines for spinal cord glioma patients.
A new study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival. The study found a correlation between an increasing number of circulating tumor cells (CTCs) and a worse outcome.
Researchers at Ohio State University found that an individual's normal genetic constitution plays a key role in driving changes in tumors during cancer development. The study compared genetic profiles of tumors from the same individual with those from other individuals, revealing similar yet distinct patterns of DNA changes.
Researchers have identified key molecules in multiple myeloma that can trigger expression of the P53 tumor suppressor gene, slowing cell growth and leading to death. The study suggests re-activating these microRNAs could provide a new treatment strategy for the disease.
A new study identifies a novel cancer-specific protein present in various types and stages of tumors. The PL2L protein might play a role in tumor initiation and progression, offering a potential target for anticancer therapies.
Researchers at Ohio State University Comprehensive Cancer Center have identified a targeted agent that promotes cell death and disrupts survival pathways in CLL cells. The agent blocks PI3K-delta, an isomer of the PI3K pathway required for hematopoietic cell functions.
The Ohio State University will enhance drug response rates and reduce adverse reactions with a $9.1 million grant for a five-year study on expression genetics in drug therapy. The project aims to identify genetic differences among individuals to predict optimal treatment and prevent side effects.
Researchers at Ohio State University have developed a new mathematical model that can plan radiation doses and schedules for high-dose therapies more efficiently. The Generalized Linear-Quadratic Model covers all dose levels and schedules, enabling faster clinical trials and earlier availability of life-saving treatments.
Researchers at Ohio State University found that breast cancer cells can regulate 14 genes simultaneously in response to estrogen-like compounds like BPA. This mechanism may contribute to cancer development and could serve as a marker for studying environmental exposure.
A new study found that an enriched environment can reduce cancer growth in mice by activating a nervous system pathway that decreases leptin levels, a hormone linked to appetite and cancer growth. The effect was observed in models of melanoma and colon cancer, with tumors reduced by up to 80% after three weeks of enrichment.
Researchers at Ohio State University discovered how dietary supplement indole-3-carbinol (I3C) blocks cancer cell growth by destroying the Cdc25A molecule. I3C reduced tumor size by up to 65% in breast cancer models, offering potential health benefits and a new strategy for cancer treatment.
A new study suggests that awake sedation for brain surgery can shorten hospital stays by 3.5 days compared to general anesthesia. The study also found a 36% decrease in post-intensive-care direct cost for cases receiving conscious sedation.
A new study reveals that cancer cells' miRNA networks are rewired and fragmented, with small clusters of two to six miRNAs existing outside the main network. This finding suggests a new approach to identifying cancer genes and targets for drug development.
Researchers at Ohio State University discovered that microRNA-155 can silence genes protecting against DNA mutations, contributing to cancer progression. The study suggests miR-155 expression may be a key stratification factor in cancer prognosis and treatment.
Researchers at Ohio State University have discovered a new molecular network that contributes to abnormal KIT protein abundance in acute leukemia cells. Targeting this network with therapeutic drugs may prove more effective than current standard of care.
Researchers have designed an experimental drug called OSU-CG12 that kills cancer cells by choking off their energy supply. The agent targets a survival mechanism used by many types of cancer, and its efficacy is 10 times better than a comparable drug, resveratrol.
Researchers discovered specific PTEN mutations linked to distinct kinds of cancer in organs targeted by Cowden syndrome. The study suggests that testing for these mutations could predict cancer severity in patients with the syndrome.
Glioblastoma cells use miR-451 to sense glucose availability, slowing cell proliferation and increasing migration. High miR-451 levels correlate with shorter survival, suggesting the molecule as a biomarker for predicting patient prognosis.
A study published in Cell reveals that loss of the molecule miR-328 is essential for progression from chronic to blast crisis phase in chronic myeloid leukemia. Maintaining this microRNA level may represent a new treatment strategy for CML blast crisis patients.
Researchers developed a mathematical model to predict cervical cancer treatment outcomes, allowing for quicker identification of non-responding tumors. The model uses MRI scans and can provide a prediction accuracy of 90 percent for local tumor control and recurrence.
Researchers found that an early immune response is key in controlling the spread of HTLV-1, a virus that causes adult T-cell leukemia and inflammatory diseases. Providing fewer immune cells for the virus to attack at a critical time can significantly reduce the infection's severity.
A new study reveals that three proteins, E2f1, E2f2 and E2f3, play a key role in the transition of stem cells to their final differentiated state. These proteins act as activators in stem cells but switch to repressors when cells begin to differentiate, and can even revert back to activators in cancer cells, promoting tumor growth.
Researchers at Ohio State University have developed a tumor-attacking virus that kills brain-tumor cells and blocks the growth of new tumor blood vessels. The virus, called RAMBO, was tested in animal models and showed promise in treating aggressive brain cancer with a survival rate of 54 days.
Research led by Ohio State University found that aggressive prostate cancers have small, irregular blood vessels, while slow-growing tumors have more normal-appearing vessels. This study suggests using tumor blood vessel architecture to guide therapy and potentially improve long-term survival for patients.
A new study published in Nature reveals that the loss of a gene called PTEN from surrounding cells can dramatically alter the tumor environment, fostering tumor growth. The findings suggest a new role for PTEN in suppressing cancer development and could lead to entirely new treatments targeting both cancer cells and their surroundings.
A new study by neuroscientists at Ohio State University suggests that immune responses to spinal cord injuries may actually worsen and extend the damage. Inhibiting antibody-producing B cells may promote healing and reduce long-term effects of spinal cord injury.
Researchers at Ohio State University found that a psychological therapy significantly relieved depressive symptoms and reduced markers of inflammation in breast cancer patients. The study published in Psychosomatic Medicine showed that treating depression can also lead to less inflammation, highlighting the importance of including psyc...
A new study suggests that changes in gene expression called epigenetic alterations can serve as markers for detecting CLL early and monitoring its progression. Researchers also point to a strategy for treating the disease earlier using drugs that reverse such changes.
Researchers at Ohio State University found that a virus discovered in a rare form of skin cancer was also present in people with the second most common type of skin cancer. The virus had a mutation that enabled it to integrate into host DNA, raising questions about its potential role in causing squamous cell carcinoma.
Researchers at Ohio State University Comprehensive Cancer Center identified a molecule, miR-21, playing an early and important role in the development of nonsmoking lung cancer. The study found that miR-21 levels were high in both early and late-stage tumors, suggesting it happens early in cancer development.
Researchers at Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveal how late-stage prostate tumors gain ability to grow without hormones. The study identifies a gene called UBE2C as key regulator in hormone-independent growth.
Researchers at Ohio State University have identified two potential anti-cancer agents that target multiple genes associated with invasive liver cancer behavior. The compounds, Resveratol and 17-allylamino-geldanamycin (17-AAG), may reverse gene changes linked to tumor progression.
Researchers at Ohio State University validated a method to measure variations in histones, promising biomarkers for chronic leukemia diagnosis and treatment response. The study accurately detected differences in histone composition between CLL cells and healthy B lymphocytes.
A team of researchers has discovered a missing trigger for calcium signaling in cells, which controls muscle contraction, nerve-cell transmission, insulin release, and other essential functions. The study found that two-pore channels (TPCs) cause the release of calcium when stimulated by NAADP, and are located in lysosomes and endosomes.
A phase II study led by Ohio State University researchers has found a targeted agent to be effective in treating advanced biliary cancer. The study showed that the agent, AZD6244, achieved an average progression-free survival of 5.4 months and stable disease in many patients.
A new study found that boosting miR-29b levels in acute myeloid leukemia cells reverses gene changes, enabling the cells to differentiate and mature. This process could lead to a drop in global DNA methylation and reactivation of tumor suppressor genes, offering a potential treatment for AML.
Researchers at Ohio State University Medical Center have discovered a gene, BDNF, that can improve insulin sensitivity, reduce fat mass, and lead to weight loss when active in the hypothalamus. The study involves injecting the gene into mice and shows promising results for treating obesity.
A study by Ohio State University researchers found that the molecule miR-29 is essential for muscle repair and maturation, but its absence is linked to rhabdomyosarcoma cancer. Raising miR-29 levels in cancer cells slowed tumor growth and induced maturity.
A new study at Ohio State University Medical Center has successfully grown human blood platelets in a laboratory for transfusion. The three-dimensional bioreactor produced up to 1.2 million platelets per day, continuing production for over 32 days.
A clinical trial at Ohio State University found that older AML patients responded well to a less toxic therapy, achieving complete remission in 42% of cases. The treatment involved decitabine and showed promising results for this 'silent majority' of patients who previously were told they had no chance of treatment.
A previously dismissed leukemia drug, flavopiridol, has shown promising results in treating CLL patients with advanced chromosomal abnormalities. In a two-phase trial involving 116 patients, approximately half responded to treatment.
Researchers at Ohio State University's Comprehensive Cancer Center discovered that mice can develop normally with just one of the four E2f genes. The study suggests that the location and timing of gene activity play a crucial role in development, contradicting previous assumptions about cancer-causing gene regulation.
A new method has been developed to accurately determine the severity of heart failure in US hospital patients, using data from 260 hospitals across the country. The model identifies key patient characteristics that predict in-hospital mortality, such as admission creatinine levels and systolic blood pressure.
A team of researchers at Ohio State University received a $10.9M NCI grant to investigate how retroviruses cause cancer in white blood cells. The five-year project aims to define critical biological events that control lymphocyte alteration and identify therapeutic targets.
A portable transcranial magnetic stimulator (TMS) device has been found to be safe and effective in eliminating headaches during the onset of migraines. The device's pulses interrupt the electrical storms in the brain that lead to throbbing head pain, offering a promising new treatment option for those suffering from chronic migraines.
Researchers at Ohio State University found that acute myeloid leukemia (AML) patients with mutations in the RAS gene are more likely to be cured when treated with high doses of cytarabine. Testing for RAS mutations may help doctors identify which AML patients should receive this therapy.
Researchers found that oncolytic viruses designed to kill cancer cells can stimulate the growth of new blood vessels to tumors, leading to regrowth and immune cell eradication. The study suggests a strategy to design combination therapies that inhibit this effect and enhance viral therapy efficacy.
The Ohio State University Center for Clinical and Translational Science will provide support services to researchers while fostering collaboration with other medical centers. The grant will accelerate research outcomes at Ohio State and elsewhere, leading to faster development of treatments for patients.
An experimental drug, OSU-HDAC42, has blocked prostate cancer progression in mice with an aggressive form of the disease. The agent reactivates genes that normally protect against cancer, shifting tumor progression to a more benign direction.
Researchers discovered a link between microRNA levels and the risk of relapse in acute myeloid leukemia (AML) patients. The study found that abnormal microRNA patterns were associated with an increased risk of recurrence, providing new insights into possible causes of the disease.